Evaluación de una intervención para reducir el tiempo de tratamiento para pacientes con TAVI (TREAT)
Evaluation d'Une Intervention Pour Reduire le Deai de Traitement Despatients Traites Par TAVI
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).
Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.
In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Brest, Francia
- Brest University Hospital
-
Rouen, Francia
- CHU de Rouen
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient over 18 years of age;
- Aortic stenosis
- Indication of TAVI
- Patient affiliated or benefiting from a health insurance scheme
- Patient having read and understood the information letter and having signed the consent form
Exclusion Criteria:
- TAVI indication not retained
- Patient who are not fluent in French and have no one around them to translate,
- Patient who do not have access to the Internet (at home or in their immediate environment)
- Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
- Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Sin intervención: Control group
The randomized centres in this group will not change their practices. |
|
|
Experimental: Patient component
The randomized centres in this group will be required to present patients with:
|
Video, booklet, website |
|
Experimental: Organisational component
The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times. |
Coronarography, CT-scan, anesthesia... |
|
Experimental: Patient and organisational components
The randomized centres in this group will have to implement the two components. |
Video, booklet, website Coronarography, CT-scan, anesthesia... |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Periodo de tiempo: Month 6
|
Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months |
Month 6
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to care, in days
Periodo de tiempo: Month 6
|
The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure |
Month 6
|
|
Mortality rate
Periodo de tiempo: Months 3 and 6
|
The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure |
Months 3 and 6
|
|
Patients' health-related quality of life
Periodo de tiempo: Baseline, Months 3 and 6
|
Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L). |
Baseline, Months 3 and 6
|
|
Patient knowledge of the disease and the TAVI procedure
Periodo de tiempo: Baseline, Month 3
|
Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score). |
Baseline, Month 3
|
|
Medication compliance
Periodo de tiempo: Month 6
|
Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance). |
Month 6
|
|
Patient satisfaction
Periodo de tiempo: Month 6
|
Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale |
Month 6
|
|
Number of visits to the patient section of the website
Periodo de tiempo: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Number of visits to the professional section of the website
Periodo de tiempo: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Acceptability of the intervention for participating centers
Periodo de tiempo: Month 6
|
The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment. |
Month 6
|
|
Intervention components' dose and fidelity
Periodo de tiempo: Month 6
|
Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol. |
Month 6
|
|
Reached populations
Periodo de tiempo: Month 6
|
Percentage of target individuals who benefit from activities of each component of the intervention |
Month 6
|
|
Intervention components' adaptation
Periodo de tiempo: Month 6
|
Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided. |
Month 6
|
|
Incremental cost-effectiveness ratio
Periodo de tiempo: Month 6
|
The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire |
Month 6
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Helene Eltchaninoff, Pr, University Hospital, Rouen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2021/0226/HP
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .